<bold>Conclusions</bold>Our results may have implications for the development of innovative therapeutic approaches based on Aurora kinase A or Plk1 inhibition associated with WEE1 blocking, aimed to improve the outcomes of patients with multi-TKI-resistant or BC CML.</p>. Here, PLK1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.